Clinical Report: Management and Outcomes of Gliomas in LMICs
Overview
This systematic review evaluates glioma management and outcomes in low- and middle-income countries (LMICs), highlighting significant disparities in treatment access and survival rates. The findings indicate that low-grade gliomas have better outcomes compared to high-grade gliomas, underscoring the need for improved healthcare infrastructure.
Background
Gliomas are the most prevalent primary malignant brain tumors, yet their management in LMICs is poorly characterized. Disparities in diagnostic capacity and treatment access contribute to suboptimal outcomes for patients in these regions. Understanding these challenges is crucial for guiding improvements in neuro-oncological care globally.
Data Highlights
Type of Glioma
5-Year OS Rate
Low-Grade Gliomas
87.8%
High-Grade Gliomas
21.9%
Key Findings
Low-grade gliomas accounted for 62.6% of tumors in the reviewed studies.
High-grade gliomas represented 37.4% of tumors.
Molecular profiling was reported in 26.7% of studies.
Pooled 5-year overall survival rates were 87.8% for low-grade gliomas and 21.9% for high-grade gliomas.
Limited access to adjuvant therapies and molecular diagnostics was noted in LMICs.
Survival outcomes in LMICs are significantly lower than those in high-income countries.
Clinical Implications
Healthcare providers in LMICs should prioritize enhancing access to adjuvant therapies and molecular diagnostics to improve glioma management. Investments in healthcare infrastructure are essential to address the disparities in treatment and outcomes observed in these regions.
Conclusion
The review highlights critical gaps in glioma management in LMICs, emphasizing the need for targeted interventions to improve patient outcomes and reduce disparities in neuro-oncological care.
by Adam M. Abdallah, Atef F. Hulliel, Asem A. Almomani, Rawhi Alshaykh, Omar H. Abuhashem, Sara Khaled Aldalki, Tala Y. Dabash, Mohammad Mukahal, Ala’ Marji, Said Mahmoud Lahham, Mouness Obeidat
